Evidence map›Paper›PMID 41125665›Full record

ArticleScientific reports2025

Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma.

Roshan Lodha, Gaelle Muller-Greven, Muhammad Asad Maqbool, Lydia Guo, Graham Buchan, Kailash Singh, Maha A Qadan, Vipin Shankar Chelakkot, Paul A Decker, Katrina Bakken and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Roshan LodhaCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, USA.
Gaelle Muller-GrevenDepartment of Cancer Science, Cleveland Clinic, 9501 Euclid Avenue, Cleveland, OH, 44195, USA.
Muhammad Asad MaqboolDepartment of Oncology, Mayo Clinic, Rochester, USA.
Lydia GuoCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, USA.
Graham BuchanCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, USA.
Kailash SinghCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, USA.
Maha A QadanDepartment of Cancer Science, Cleveland Clinic, 9501 Euclid Avenue, Cleveland, OH, 44195, USA.
Vipin Shankar ChelakkotDepartment of Cancer Science, Cleveland Clinic, 9501 Euclid Avenue, Cleveland, OH, 44195, USA.
Paul A DeckerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, USA.
Katrina BakkenDepartment of Radiation Oncology, Mayo Clinic, Rochester, USA.
Brett L CarlsonDepartment of Radiation Oncology, Mayo Clinic, Rochester, USA.
Danielle BurgenskeDepartment of Radiation Oncology, Mayo Clinic, Rochester, USA.
Amy S NowackiDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA.
George VasmatzisDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, USA.
Sani H KizilbashDepartment of Oncology, Mayo Clinic, Rochester, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, USA.
Candece L GladsonCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, USA. gladsoc@ccf.org.

Funding

Endocytic Trafficking of ADCs in GBM cancer stem-like cellsR01NS111981 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI CATHLEEN R CARLIN, Candece L Gladson · 2019 to 2026
$2.3M
Endogenous synthesis of TRAIL by glioma cancer stem cells and resistance to TRAIL therapyR56NS134148 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI GLADSON, CANDECE L, KALAFATIS, MICHAEL · 2023 to 2023
$478k
NINDS NIH HHS R01 NS111981NINDS NIH HHS R01NS111981NINDS NIH HHS R56 NS134148
6 · The paper itself

Abstract

Glioblastoma, IDH wild-type (WHO grade 4) (GBM), is the most common primary brain tumor in adults with a 21-month median overall survival, despite surgical-resection and radio-chemotherapy. Bevacizumab, a monoclonal antibody towards vascular endothelial growth factor-A, is used to treat recurrent-GBM. To find predictors of poor-response, patient-derived xenograft (PDX)-tumors were treated with bevacizumab or vehicle and subsequently grouped based on survival-response; RNAseq expression was then compared by responder-status. Bioinformatic-analysis demonstrated differential gene expression in tumors from poor-responders (six-PDXs) as compared to tumors from good-responders (three-PDXs), along with upregulation of angiogenesis and collagen gene-sets in poor-responders. Within these gene-sets, multiple genes known to be regulated by the early growth response-1 (EGR1) transcription factor, which was also upregulated, were identified and CHRNA7 (α7-nicotinic-acetylcholine receptor, α7-nAChR) was selected for validation. In terms of protein/functional studies, in the bevacizumab-treated poor-responders, nuclear-EGR1 was elevated, Ki67-labeling was increased in EGR1

Indexed as

BevacizumabBrain NeoplasmsDrug Resistance, NeoplasmGlioblastomaTranscriptomeAnimalsAntineoplastic Agents, ImmunologicalDNA Modification MethylasesDNA Repair EnzymesEarly Growth Response Protein 1FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceAntineoplastic Agents, ImmunologicalBevacizumabDNA Modification MethylasesDNA Repair EnzymesEarly Growth Response Protein 1EGR1 protein, humanMGMT protein, humanTumor Suppressor ProteinsAngiogenesisBevacizumabCHRNA7EGFREGR1GlioblastomaMGMTProliferationPTENSexα7-nAChR

Identifiers

PMID41125665
PMCPMC12546648

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.